Glioblastoma stage 4 survival

Glioblastoma (GBM) is the most aggressive malignant tumor of the central nervous system, and its stage 4 is classified as the highest grade (WHO grade IV). Patient survival time is related to many factors such as age, treatment method, tumor location and molecular characteristics.

1. Mean survival time: Even with standard treatment, the average median survival time of GBM patients is usually 12-15 months, and only 5%-10% of patients survive more than 5 years. People who don't receive treatment usually live only a few months.

2. The impact of standard treatment: Standard treatment includes the combination of surgical resection, radiotherapy and temozolomide (Temozolomide) chemotherapy. As complete tumor resection as possible can help prolong survival, and temozolomide combined with radiotherapy can improve median survival to 14.6 months.

3. The role of molecular characteristics: The survival prognosis of GBM patients is closely related to molecular markers. For example, patients with promoter methylation of O6-methylguanine-DNAmethyltransferase (MGMT) are more sensitive to temozolomide chemotherapy, and their survival may be significantly prolonged. Additionally, isocitrate dehydrogenase1 (IDH1) mutations are associated with longer survival.

4. Exploration of new treatments: In recent years, new methods such as immunotherapy (such asCAR-Tcell therapy, checkpoint inhibitors), gene therapy and tumor electric field therapy (TTFields) are being studied, but their clinical benefits still need to be further verified.

5. Personalization factors: Patients who are younger, have better physical status, and have fewer comorbidities usually have a better prognosis. Due to the high heterogeneity of the disease, individualized treatment plans and multidisciplinary collaboration are particularly important.

(Click to view an introduction to drugs for the treatment of glioblastoma.)

xa0

Reference materials:

1.Stupp R, et al. "Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma." N Engl J Med, 2005.

2.National Cancer Institute. Glioblastoma Treatment Overview. https://www.cancer.gov

3.American Brain Tumor Association. Glioblastoma Information. https://www.abta.org